Digital Therapeutics Market Analysis

Application (Diabetes, Obesity, CVD, Respiratory Diseases, Smoking Cessation, CNS Diseases)

Diabetes segment is set to capture over 29% digital therapeutics market share by 2037. The segment's tremendous growth rate can be propelled by increasing diabetes and several other chronic diseases, which demand a personalized solution for treating patients. According to a report by the International Diabetes Federation in 2021, more than 537 million adults had diabetes in 2021, which is expected to cross 643 million by 2030 and is projected to surpass 783 million by 2045.

Moreover, obesity is poised to hold the second-largest share in this segment, driven by the tremendous growth in the population suffering from obesity. The World Health Organization estimated that in 2024, globally, the data on the obese population has doubled since 1990; meanwhile, adolescent obesity has shown a lucrative growth rate of four times. In addition, in 2022, more than 43% of adults were projected to be overweight, out of which 16% lived with obesity.

End-users (Patients, Providers, Employers, Payers)

By the end of 2037, digital therapeutics segment is expected to capture around 35% digital therapeutics market share due to the increase in patients, healthcare support for health issues and needs, and demand for healthcare. There is also a greater focus on providing more personalized and better care to elderly patients. According to a report by the Census in 2020, the U.S. population above the age of 65 increased by more than 38% from 2010 to 2020 in 10 years. Patients receive individualized care plans based on evidence.

Additionally, digital medicines can assist people-especially those living in rural and isolated areas—to have better access to care.

Our in-depth analysis of the market includes the following segments: